49,696 Shares in Xencor, Inc. $XNCR Purchased by The Manufacturers Life Insurance Company

by · The Markets Daily

The Manufacturers Life Insurance Company acquired a new position in Xencor, Inc. (NASDAQ:XNCR – Free Report) in the second quarter, Holdings Channel reports. The fund acquired 49,696 shares of the biopharmaceutical company’s stock, valued at approximately $800,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Xencor during the 2nd quarter worth approximately $219,785,000. BVF Inc. IL boosted its stake in shares of Xencor by 160.3% in the 4th quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock worth $109,217,000 after buying an additional 4,393,579 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of Xencor by 603.7% in the third quarter. Legal & General Group Plc now owns 1,273,000 shares of the biopharmaceutical company’s stock valued at $14,932,000 after acquiring an additional 1,092,095 shares in the last quarter. State Street Corp increased its position in shares of Xencor by 22.7% during the fourth quarter. State Street Corp now owns 4,507,254 shares of the biopharmaceutical company’s stock valued at $69,006,000 after acquiring an additional 833,423 shares during the last quarter. Finally, Johnson & Johnson purchased a new stake in shares of Xencor during the second quarter valued at approximately $12,043,798.

Analyst Ratings Changes

A number of analysts recently commented on the company. Wedbush lifted their price target on Xencor from $26.00 to $30.00 and gave the stock an “outperform” rating in a report on Thursday, August 6th. Cantor Fitzgerald raised their target price on Xencor from $43.00 to $44.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research note on Wednesday, June 24th. Truist Financial cut their price target on shares of Xencor from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Finally, Zacks Research upgraded shares of Xencor from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $30.71.

Check Out Our Latest Stock Report on Xencor

Xencor Trading Down 0.0%

Xencor stock opened at $26.61 on Friday. The business’s 50 day simple moving average is $21.06 and its 200 day simple moving average is $15.30. Xencor, Inc. has a 12 month low of $8.19 and a 12 month high of $30.61. The company has a market cap of $1.98 billion, a price-to-earnings ratio of -12.26 and a beta of 0.88.

Xencor (NASDAQ:XNCR – Get Free Report) last released its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.51. The business had revenue of $51.22 million during the quarter, compared to the consensus estimate of $18.89 million. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%.The business’s revenue for the quarter was up 17.4% on a year-over-year basis. During the same period last year, the business posted ($0.41) earnings per share. As a group, equities research analysts forecast that Xencor, Inc. will post -3 earnings per share for the current fiscal year.

About Xencor

(Free Report)

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.

See Also

Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor, Inc. (NASDAQ:XNCR – Free Report).